Methods, compositions, systems, and packaging are disclosed for reducing postoperative nausea and/or vomiting (PONV) in a human patient in need of general anesthesia for surgery. Such methods may include scheduling a surgery for the human patient, and administering to the patient one or more series of prescribed medicines for at least three successive days during a regimen immediately preceding general anesthesia. Compositions may include cholinergic receptor agonists, muscarinic receptor agonists, dopamine receptor agonists, MAO inhibitors, serotonin receptor agonists, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin releasing agents, serotonin-norepinephrine-dopamine reuptake inhibitors, opioids, or analgesics.

Methods, compositions, systems, and packaging are disclosed for reducing postoperative nausea and/or vomiting (PONV) in a human patient in need of general anesthesia for surgery. Such methods may include scheduling a surgery for the human patient, and administering to the patient one or more series of prescribed medicines for at least three successive days during a regimen immediately preceding general anesthesia. Compositions may include cholinergic receptor agonists, muscarinic receptor agonists, dopamine receptor agonists, MAO inhibitors, serotonin receptor agonists, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin releasing agents, serotonin-norepinephrine-dopamine reuptake inhibitors, opioids, or analgesics.

Methods, compositions, systems, and packaging are disclosed for reducing postoperative nausea and/or vomiting (PONV) in a human patient in need of general anesthesia for surgery. Such methods may include scheduling a surgery for the human patient, and administering to the patient one or more series of prescribed medicines for at least three successive days during a regimen immediately preceding general anesthesia. Compositions may include cholinergic receptor agonists, muscarinic receptor agonists, dopamine receptor agonists, MAO inhibitors, serotonin receptor agonists, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin releasing agents, serotonin-norepinephrine-dopamine reuptake inhibitors, opioids, or analgesics.

A nicotine oral delivery product contains a powder enclosed in a water insoluble pouch, wherein the pouch is permeable for saliva and therein dissolved parts of the powder, wherein the powder comprises at least (a) nicotine selected from the group consisting of tobacco, nicotine salts, nicotine base, stabilized nicotine, and mixtures thereof corresponding to 0.1 to 20 mg nicotine in the form of nicotine base and (b) a chewing gum composition. A method is provided for producing the nicotine oral delivery product.

A nicotine oral delivery product contains a powder enclosed in a water insoluble pouch, wherein the pouch is permeable for saliva and therein dissolved parts of the powder, wherein the powder comprises at least (a) nicotine selected from the group consisting of tobacco, nicotine salts, nicotine base, stabilized nicotine, and mixtures thereof corresponding to 0.1 to 20 mg nicotine in the form of nicotine base and (b) a chewing gum composition. A method is provided for producing the nicotine oral delivery product.

The invention relates to a chewing gum comprising at least a gum core comprising nicotine polacrilex, at least a one outer coating covering the core, comprising at least one sugar alcohol or mixtures of sugar alcohols and, at least a one portion fused onto the outer coating, wherein the portion comprises nicotine bitartrate or nicotine ditartrate dihydrate and at least one sugar alcohol or a mixture of sugar alcohols and at least one buffer present in the coating and/or in a portion fused to the coating.

The invention relates to a chewing gum comprising at least a gum core comprising nicotine polacrilex, at least a one outer coating covering the core, comprising at least one sugar alcohol or mixtures of sugar alcohols and, at least a one portion fused onto the outer coating, wherein the portion comprises nicotine bitartrate or nicotine ditartrate dihydrate and at least one sugar alcohol or a mixture of sugar alcohols and at least one buffer present in the coating and/or in a portion fused to the coating.

A pulmonary delivery system includes an elongated body having an openable and closeable portion thereof for receiving an insertable and replaceable container such as a cartridge of pure medical product disposed in a saline solution. The medical product may be epinephrine, insulin or nicotine disposed in a saline solution. The system also incorporates a penetrating element that is disposed in the cylinder to pierce the cartridge and release the nicotine solution into the cylinder and into or on a micron mesh grid. A flow of air created by inhaling through a mouthpiece draws air into an individual's lungs from an entrainment port and onto a grid for atomizing a mist of micron droplets through the grid. It is recognized that the air from the entrainment port further dilutes the concentration of the medical product. The grid is connected to a source of electrical power to vibrate the mesh grid.

A pulmonary delivery system includes an elongated body having an openable and closeable portion thereof for receiving an insertable and replaceable container such as a cartridge of pure medical product disposed in a saline solution. The medical product may be epinephrine, insulin or nicotine disposed in a saline solution. The system also incorporates a penetrating element that is disposed in the cylinder to pierce the cartridge and release the nicotine solution into the cylinder and into or on a micron mesh grid. A flow of air created by inhaling through a mouthpiece draws air into an individual's lungs from an entrainment port and onto a grid for atomizing a mist of micron droplets through the grid. It is recognized that the air from the entrainment port further dilutes the concentration of the medical product. The grid is connected to a source of electrical power to vibrate the mesh grid.

A nicotine oral delivery product includes a composition enclosed in a water insoluble pouch, wherein the pouch is permeable for saliva and dissolved compounds of the composition, the composition including a source of nicotine and a cellulose or cellulose derivative, wherein the cellulose or cellulose derivative is in granular form. A method of making the nicotine oral delivery product is also provided.